Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose-Finding and Proof-of-Concept Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

NCT05145816 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.

NCT NCT05145816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05145816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose-Finding and Proof-of-Concept Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
Lead sponsor
University of Texas Southwestern Medical Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 15, 2024
Completion date
September 1, 2027
Enrollment
37 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

al amyloidosis, amyloidosis